Aerpio Pharmaceuticals, Inc. (ARPO)
Stock Price:
$1.28 USD
-0.06 (-4.48%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $1.39 +0.11 (8.59%) Oct 26, 4:47 PM
Key Info
| Market Cap |
53.85M |
| Revenue (ttm) |
15.00M |
| Net Income (ttm) |
-3.74M |
| Shares Out |
42.07M |
| EPS (ttm) |
-0.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$1.28 |
| Previous Close |
$1.34 |
| Change ($) |
-0.06 |
| Change (%) |
-4.48% |
| Day's Open |
1.34 |
| Day's Range |
1.25 - 1.36 |
| Day's Volume |
3,167,823 |
| 52-Week Range |
0.42 - 1.90 |
More Stats
| Market Cap |
53.85M |
| Enterprise Value |
9.08M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
42.07M |
| Float |
34.41M |
| EPS (basic) |
-0.09 |
| EPS (diluted) |
-0.09 |
| FCF / Share |
-0.08 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.47M |
| Short Ratio |
1.00 |
| Short % of Float |
4.27% |
| Beta |
1.96 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.59 |
| PB Ratio |
1.32 |
| Revenue |
15.00M |
| Operating Income |
-4.48M |
| Net Income |
-3.74M |
| Free Cash Flow |
-3.29M |
| Net Cash |
44.76M |
| Net Cash / Share |
1.06 |
| Gross Margin |
100.00% |
| Operating Margin |
-29.89% |
| Profit Margin |
-24.90% |
| FCF Margin |
-21.95% |
| ROA |
-4.64% |
| ROE |
-8.46% |
| ROIC |
233.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
0 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Low
2.00
Current: $1.28
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | 20.16 | - | - | - |
| Gross Profit | - | 20.16 | - | - | - |
| Operating Income | -24.44 | -11.18 | -21.39 | -16.63 | -0.02 |
| Net Income | -23.27 | -10.40 | -21.40 | -16.98 | -0.03 |
| Shares Outstanding | 40.59 | 33.93 | 21.67 | 0.85 | 5.00 |
| Earnings Per Share | -0.57 | -0.31 | -1.03 | -24.52 | -0.01 |
| Operating Cash Flow | -23.85 | -5.81 | -18.88 | -15.72 | -0.02 |
| Capital Expenditures | -0.24 | -0.04 | -0.01 | -0.11 | - |
| Free Cash Flow | -24.09 | -5.85 | -18.89 | -15.83 | -0.02 |
| Cash & Equivalents | 38.56 | 62.65 | 20.29 | 1.68 | 0.02 |
| Total Debt | 0.17 | - | - | 12.39 | 0.16 |
| Net Cash / Debt | 38.39 | 62.65 | 20.29 | -10.71 | -0.14 |
| Assets | 39.94 | 64.12 | 21.03 | 2.40 | 0.02 |
| Liabilities | 3.40 | 5.46 | 3.59 | 88.62 | 0.21 |
| Book Value | 36.54 | 58.67 | 17.44 | -86.22 | -0.19 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aerpio Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Joseph H. Gardner |
Stock Information
| Ticker Symbol |
ARPO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARPO |
Description
Aerpio Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.